Professional Documents
Culture Documents
Pi Is 2352396419307893
Pi Is 2352396419307893
EBioMedicine
journal homepage: www.elsevier.com/locate/ebiom
Commentary
https://doi.org/10.1016/j.ebiom.2019.11.040
2352-3964/© 2019 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
12 M. Noguera-Julian / EBioMedicine 50 (2019) 11 12
inexperienced users that are guided by ad hoc created companion [3] Gu€ nthard HF, Calvez V, Paredes R, Pillay D, Shafer RW, Wensing AM, et al. Human
tools in carefully designed feasibility tests. Of note, ad hoc mobile immunodeficiency virus drug resistance: 2018 recommendations of the interna-
tional antiviral society-USA panel. Clin Infect Dis 2019;68:177–87.
software not only increases test robustness and usability but may [4] Inzaule SC, Ondoa P, Peter T, Mugyenyi PN, Stevens WS, de Wit TFR, et al. Afford-
also be an entry point to controlled data collection for surveillance. able HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-
While such PoC technology deployment into a real-world setting Saharan Africa. Lancet Infect Dis 2016;16:e267–75.
[5] Noguera-Julian M, Edgil D, Harrigan PR, Sandstrom P, Godfrey C, Paredes R. Next-
faces challenges such as materials, continued supply, and cold chain Generation human immunodeficiency virus sequencing for patient management
maintenance that demand operational research and cost-benefit and drug resistance surveillance. J Infect Dis 2017;216:S829–33.
studies [10], work by Panpradist et al. represents an important step [6] Duarte HA, Panpradist N, Beck IA, Lutz B, Lai J, Kanthula RM, et al. Current status of
point-of-care testing for human immunodeficiency virus drug resistance. J Infect
forward for HIV drug resistance testing.
Dis 2017;216:S824–8.
[7] Panpradist N, Beck IA, Chung MH, Kiarie JN, Frenkel LM, Lutz BR. Simplified paper
Declaration of Competing Interest format for detecting HIV drug resistance in clinical specimens by oligonucleotide
ligation. PLoS One 2016;11:e0145962.
[8] MacLeod IJ, Rowley CF, Essex M. PANDAA-monium: intentional violations of con-
None. ventional qPCR design enables rapid, HIV-1 subtype-independent drug resistance
SNP detection. BioRxiv 2019:795054. doi: 10.1101/795054.
References [9] Panpradist N, Beck IA, Vrana J, Higa N, McIntyre D, Ruth PS, et al. OLA-Simple: A
software-guided HIV-1 drug resistance test for low-resource laboratories. EBio-
Medicine 2019;50:33–43.
[1] Mega ER. Alarming surge in drug-resistant HIV uncovered. Nature 2019. doi: [10] Drain PK, Hyle EP, Noubary F, Freedberg KA, Wilson D, Bishai WR, et al. Diagnostic
10.1038/d41586-019-02316-x. point-of-care tests in resource-limited settings. Lancet Infect Dis 2014;14:239–49.
[2] Global action plan on HIV drug resistance 2017-2021. Geneva: World Health
Organization; 2017.